Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rare Diseases: US FDA Gives More Guidance On Premarket Safety Evaluation, Historical Controls

Executive Summary

Agency specifies several approaches to augment safety assessment in a new draft guidance, which also encourages participation by patients and their advocates in the drug development process.


Advertisement

Related Content

Nearly 9% FY 2019 Increase For FDA In Shutdown-Averting Appropriations Bill
US FDA Wins Big In Shutdown-Averting Approps Bill
Patient Experience Data: US FDA Guidance Offers Other Ways To Share
Disease-Specific Guidances Reflect US FDA's 'Nimble, Collaborative, Patient-Focused' Approach
As Orphan Drugs Gain More Attention, FDA Releases Development Guidance
Duchenne Muscular Dystrophy: FDA Supports Broader Outcome Measures, Biomarkers

Topics

Advertisement
UsernamePublicRestriction

Register

PS124677

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel